Original Title: 전립선암에서 로봇수술의 경제성 분석

Authors' recommendations: We assessed the clinical effectiveness and cost-effectiveness of RARP compared to LRP and ORP for localized prostate cancer in South Korea. The economic efficiency of different surgical procedures for RP was measured using a decision-analysis model built over 1year, based on the perspective of the health insurance system. The incremental cost-effectiveness ratio (ICER) of RARP was 132,507,255KRW per quality-adjusted life year (QALY) compare to ORP, and 252,141,944 KRW compare to LRP (exchange rate 1 dollar=1,100KRW). Considering the threshold value of 30.50 million KRW, RARP cannot be considered as a cost effective alternative compared to conventional surgeries. The utility value and RARP cost were confirmed as sensitive variables through one-way sensitivity analysis, and the outcome did not affect the results, which demonstrated that RARP was not cost-effective. The results of the present study should be interpreted with caution as short-term data were used for cost-effectiveness analysis and a retrospective research design was used to assess the clinical effectiveness. Based on the results of our study, long-term prospective studies are necessary to yield superior results.

Project Status: Completed

Year Published: 2015

URL for published report: https://www.neca.re.kr/lay1/program/S1T11C145/report/view.do?seq=157

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: South Korea

Organisation Name: National Evidence-based healthcare Collaborating Agency

Contact Address: National Evidence-based Healthcare Collaborating Agency (NECA), 3~5F Health and Welfare Social Administration B/D, 400 Neungdong-ro, Gwangjin-gu, Seoul, Korea.

Contact Name: int@neca.re.kr

Contact Email: int@neca.re.kr

Copyright: National Evidence-based Healthcare Collaborating Agency (NECA)